AJP - Regulatory, Integrative and Comparative Physiology, Vol 273, Issue 1 371-R378, Copyright © 1997 by American Physiological Society

ARTICLES

Acute alterations in growth hormone-insulin-like growth factor axis in humans injected with endotoxin

C. H. Lang, V. Pollard, J. Fan, L. D. Traber, D. L. Traber, R. A. Frost, M. C. Gelato and D. S. Prough
Department of Surgery, State University of New York at Stony Brook 11794-8191, USA. clang@cmp.hmc.psu.edu

The purpose of the present study was to characterize the acute changes in the insulin-like growth factor (IGF) system in humans after administration of endotoxin (lipopolysaccharide; LPS). Escherichia coli LPS (4 ng/kg) was injected intravenously into healthy adults, and serial blood samples were collected for the next 5 h; subjects injected with saline served as time-matched controls. LPS administration resulted in a gradual decrease in the total extractable IGF-I concentration, which was reduced by approximately 20% over the final 2 h of the experiment; levels of free IGF-I were not significantly altered. LPS also produced a marked but transient elevation in growth hormone (GH) concentration. IGF-binding protein (BP)-1 levels were elevated more than fivefold 2 h after LPS injection, and thereafter levels gradually returned toward baseline. IGFBP-2 concentration also increased after LPS injection, but the maximal increase (approximately 50% above basal) was observed during the final 2 h of the protocol. In contrast, IGFBP-3 levels did not vary over the period examined in response to LPS, and there was no apparent increase in number of BP-3 proteolytic fragments. Cortisol levels were increased early and remained two- to threefold above baseline throughout the protocol. No significant alterations in serum concentration of glucose or insulin were noted. LPS also produced an early elevation in tumor necrosis factor and a later increase in interleukin-6. These data indicate that the acute changes in the GH-IGF axis in humans in response to LPS are comparable with those observed in humans in other traumatic conditions and in animal models of endotoxemia and infection.

This article has been cited by other articles:

				M. Granado, A. I. Martin, M. Lopez-Menduina, A. Lopez-Calderon, and M. A. Villanua GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E131 - E141. [Abstract] [Full Text] [PDF]

				Y. Chen, D. Sun, V. M. R. Krishnamurthy, and R. Rabkin Endotoxin attenuates growth hormone-induced hepatic insulin-like growth factor I expression by inhibiting JAK2/STAT5 signal transduction and STAT5b DNA binding Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1856 - E1862. [Abstract] [Full Text] [PDF]

				J. A. Daniel, T. H. Elsasser, A. Martinez, B. Steele, B. K. Whitlock, and J. L. Sartin Interleukin-1{beta} and tumor necrosis factor-{alpha} mediation of endotoxin action on growth hormone Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E650 - E657. [Abstract] [Full Text] [PDF]

				L. Q. Hong-Brown, C. R. Brown, R. N. Cooney, R. A. Frost, and C. H. Lang Sepsis-induced muscle growth hormone resistance occurs independently of STAT5 phosphorylation Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E63 - E72. [Abstract] [Full Text] [PDF]

				M. Soop, H. Duxbury, A. O Agwunobi, J. M. Gibson, S. J. Hopkins, C. Childs, R. G. Cooper, P. Maycock, R. A. Little, and G. L. Carlson Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans Am J Physiol Endocrinol Metab, June 1, 2002; 282(6): E1276 - E1285. [Abstract] [Full Text] [PDF]